Evidence map›Paper›PMID 39984473›Full record

Articlenpj aging2025

Early vascular aging ambulatory score in acute ischemic stroke.

Nikolaos Kakaletsis, Vasilios Kotsis, Naohisa Hosomi, Tomohisa Nezu, Patrik Michel, Thevoz Guillaume, Davide Strambo, Young Seo Kim, Wonjae Sung, Konstantinos Vemmos and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in npj aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Impact of vascular aging on stroke prognosis: the novel severity and arterial stiffness (SASt) score.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Nikolaos KakaletsisFirst Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece. kakaletsisnikos@yahoo.gr.
Vasilios KotsisThird Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece.
Naohisa HosomiDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
Tomohisa NezuDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
Patrik MichelStroke Center and Neurology Service, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Thevoz GuillaumeStroke Center and Neurology Service, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Davide StramboStroke Center and Neurology Service, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Young Seo KimDepartment of Neurology, College of Medicine, Hanyang University, Seoul, Republic of Korea.
Wonjae SungDepartment of Neurology, College of Medicine, Hanyang University, Seoul, Republic of Korea.
Konstantinos VemmosDepartment of Clinical Therapeutics of Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Eleni KorompokiDepartment of Clinical Therapeutics of Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Maurizio AcampaStroke Unit, Department of Medical Sciences, Surgery and Neurosciences, "Santa Maria Alle Scotte" General Hospital, University of Siena, Siena, Italy.
Jukka PutaalaDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Lauri TulkkiDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Matthias HermannUniversity Heart Center Zurich, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
Protazy RejmerUniversity Heart Center Zurich, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
Philip M BathStroke Trials Unit, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, UK.
Lisa J WoodhouseStroke Trials Unit, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, UK.
Athanase D ProtogerouCardiovascular Prevention & Research Unit, Clinic & Laboratory of Pathophysiology, Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Elpida AthanasopoulouCardiovascular Prevention & Research Unit, Clinic & Laboratory of Pathophysiology, Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Haralampos MilionisDepartment of Internal Medicine, Medical School, University of Ioannina, University Hospital of Ioannina, Ioannina, Greece.
George NtaiosDepartment of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Christos SavopoulosFirst Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the impact of early vascular aging (EVA) on acute ischemic stroke (AIS) outcomes may provide new insights for improving prognostic assessments and developing targeted therapeutic strategies. This study aimed to validate the EVA ambulatory score (EVAAs) in AIS patients, assessing its association with stroke type, severity, and prognosis. Among the 2,730 AIS patients with a mean age of 72.0 ± 14.4 years, 83.4% exhibited EVA. EVA was identified as an independent predictor of poor outcome at both discharges (aOR:1.72, 95%CI:1.25-2.36, p < 0.001) and at 90 days (aOR:2.22, 95%CI:1.49-3.31, p < 0.001). In subgroup analyses, EVAAs showed improved predictive value in AIS patients with a lower cardiovascular disease burden and a non-atherogenic lipid profile. The EVAAs, as an indicator of EVA that could be easily integrated into daily clinical practice, are a significant predictor of adverse outcomes in AIS patients.

Identifiers

PMID39984473
PMCPMC11845580

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.